α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study

The Lancet Neurology

Volumn 10, Issue 3, 2011, Pages 230-240

  Mollenhauer, Brit ^a,b,e   Locascio, Joseph J ^c   Schulz Schaeffer, Walter ^b   Sixel Döring, Friederike ^a   Trenkwalder, Claudia ^a,b   Schlossmacher, Michael G ^d,e  

^a Paracelsus Elena Klinik   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIFFUSE LEWY BODY DISEASE; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR FLUID; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NORMOTENSIVE HYDROCEPHALUS; PARKINSON DISEASE; PARKINSONISM; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SYNUCLEINOPATHY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; TAU PROTEINS;

EID: 79951720856     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70014-X     Document Type: Article

References (42)

1. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
2. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006, 349:162-166.
3. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008, 213:315-325.
4. Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. Neurosci Lett 2009, 450:332-335.
5. Noguchi-Shinohara M, Tokuda T, Yoshita M, et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 2009, 1251:1-6.
6. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 2009, 16:363-369.
7. Kasuga K, Tokutake T, Ishikawa A, et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010, 81:608-610.
8. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
9. Reesink FE, Lemstra AW, van Dijk KD, et al. CSF alpha-synuclein does not discriminate dementia with lewy bodies from Alzheimer's disease. J Alzheimers Dis 2010, 22:87-95.
10. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
11. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010, 4:683-699.
12. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
13. Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010, 133:2045-2057.
14. Brooks DJ Imaging dopamine transporters in Parkinson's disease. Biomark Med 2010, 4:651-660.
15. Schlossmacher MG, Mollenhauer B Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Biomark Med 2010, 4:647-650.
16. Schulz-Schaeffer WJ The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010, 120:131-143.
17. Wiltfang J, Lewczuk P, Riederer P, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005, 6:69-84.
18. Gibb WR Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 1988, 64:345-351.
19. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
21. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
22. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
23. Folstein MF, Folstein SE, McHugh PR " Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
24. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007, 68:812-819.
25. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Roentgenol 1987, 149:351-356.
26. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005, 57(3 suppl):S4-S16.
27. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996, 47:1-9.
28. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
29. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
30. Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA 2008, 105:10907-10912.
31. Blennow K, Hampel H, Weiner M, Zetterberg H Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144.
32. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006, 22:200-208.
33. Baker SG, Kramer BS Peirce, Youden and the receiver operating characteristic curves. Am Stat 2007, 61:343-346.
34. Oertel WH, Schulz JB Parkinson-Syndrome 2003, Kohlhammer-Verlag, Stuttgart.
35. Lewitt PA Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008, 359:2468-2476.
36. Mattsson N, Blennow K, Zetterberg H Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 2010, 48:603-607.
37. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008, 64:239-246.
38. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 2005, 112:1613-1624.
39. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009, 106:13010-13015.
40. Frasier M, Chowdhury S, Eberling J, et al. Biomarkers in Parkinson's disease: a funder's perspective. Biomark Med 2010, 4:723-729.
41. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord 2010, 25:560-569.
42. Tomlinson J, Cullen V, Schlossmacher MG Identifying targets in alpha-synuclein metabolism to treat Parkinson's and related disorders. Protein misfolding diseases: current and emerging principles and therapies 2010, 817-841. John Wiley and Son, Hoboken, NJ. M. Ramirez-Alvarado, J.W. Kelly, C.M. Dobson (Eds.).